NRX NurExone Biologic Inc.

0.3425USD0.4900 CAD · TSXV+2.08%Mkt Cap: 31.53M USDP/E: —

NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries. It offers ExoPTEN, for treatment of a…

Key Statistics

Company
Market Cap31.53M USD
Enterprise Value32.35M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-6.38M USD
Revenue/Share—
Last Price0.3425 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees—
CountryCA
SectorHealthcare
IndustryBiotechnology
ISINCA67059R1091
Valuation
P/E (Trailing)—
P/E (Forward)-5.93
PEG—
EV/EBITDA-7.65
EV/Revenue—
P/S—
P/B26.84
EPS (TTM)-0.11 USD
EPS (Forward)-0.08 USD
52W Range
0.304117% of range0.5313
52W High0.5313 USD
52W Low0.3041 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-231.47%
ROA-156.36%
ROIC-686.15%
ROCE-204.36%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-4.51M USD
CapEx (TTM)55.00K USD
FCF Margin—
FCF Yield-5.08%
Net Debt-954.00K USD
Net Debt/EBITDA0.16
Net Debt/FCF—
Balance Sheet
Debt/Equity0.04
Current Ratio1.21
Quick Ratio1.18
Book Value/Sh0.02 USD
Cash/Share0.01 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.92.05M
Float91.89M
Insiders6.24%
Institutions0.00%
Short Interest
Short Ratio0.0d
Short % Out.0.00%
Shares Short44
Short (prev mo.)12.19K
Technical
SMA 500.3943 (-13.1%)
SMA 2000.4064 (-15.7%)
Beta0.34
S&P 52W Chg12.00%
Avg Vol (30d)11.62K
Avg Vol (10d)9.12K
Technical Indicators
RSI (14)45.3
MACD-0.0268
MACD Signal-0.0283
MACD Hist.+0.0016
BB Upper0.3853 USD
BB Middle0.3457 USD
BB Lower0.3060 USD
BB Width22.95%
ATR (14)0.0173 USD
Vol Ratio (20d)0.16x

About NurExone Biologic (CVE: NRX)

›

NurExone Biologic (CVE: NRX) is listed on the TSX Venture Exchange, where its shares trade in CAD. It belongs to the Biotechnology industry, part of the Healthcare sector.

The shares were at 0.4900 CAD on 19 November 2026, down 31.0% over 52 weeks. Its 52-week range is 0.4350 CAD to 0.7600 CAD: the price is 35.5% below the high and 12.6% above the low.

Its market capitalisation is 45.10M CAD.

NurExone Biologic reports return on equity of -231.5% and an operating margin of 0.0%.

It holds more cash than debt, a net cash position of 954.00K USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. The next earnings report is expected on 25 November 2026.